Welcome to our dedicated page for ProQR Therapeutics N.V. SEC filings (Ticker: PRQR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ProQR Therapeutics N.V. filings document a Nasdaq-listed foreign private issuer furnishing Form 6-K current reports for its RNA therapeutics business. The disclosures describe the Axiomer RNA editing platform, ADAR-mediated oligonucleotide design, pipeline programs including AX-0810, AX-2402 and AX-2911, scientific presentations, collaborations, and annual operating and financial results.
The filing record also covers governance and capital-market matters, including annual general meeting notices, agenda materials, proxy forms, proposed articles-of-association amendments, board nominations and board-composition updates. Several Form 6-K reports incorporate company materials by reference into Form F-3 registration statements, linking current business updates with registered securities disclosure.
ProQR Therapeutics N.V. has a shareholder group of Netherlands-based entities and portfolio manager Patrick Johan Hendrik Krol reporting holdings of its ordinary shares on a Schedule 13G/A, based on 141,121,476 ordinary shares outstanding.
Aescap Life Sciences directly holds 4,156,878 shares, or about 2.95% of the class, and Aescap Genetics holds 1,310,271 shares, or 0.93%. Inspirational Visions holds 35,411 shares, or 0.03%. Privium Fund Management B.V., as fund manager of Aescap Life Sciences and Aescap Genetics, may be deemed to beneficially own 5,467,149 shares, or 3.87%.
Through his roles with these entities and a direct holding of 26,302 shares, Krol may be deemed to beneficially own 5,528,862 ProQR shares, or approximately 3.92% of the outstanding ordinary shares. All reporting persons are described as having sole voting and sole dispositive power over their respective positions, with no shared authority reported.
ProQR Therapeutics N.V. Chief Executive Officer Daniel Anton de Boer reported an open-market purchase of 150,000 Ordinary Shares of the company on 9 July 2026 at a price of $1.74 per share. Following this transaction, he directly holds 300,000 Ordinary Shares of ProQR Therapeutics.
ProQR Therapeutics N.V. reported that Chief Executive Officer Daniel Anton de Boer bought Ordinary Shares in the company. On July 7, 2026, he made an open-market purchase of 150,000 Ordinary Shares at $1.59 per share. After this transaction, he directly owns 150,000 Ordinary Shares, indicating this was a new position or a reset position as reflected in this filing.
ProQR Therapeutics N.V. filed a Form F-3 shelf prospectus to register for resale up to 3,030,303 ordinary shares held by a selling shareholder pursuant to a Share Purchase Agreement. The registration is for resale only; ProQR will not receive proceeds and the shares may be sold from time to time after effectiveness.
The prospectus states ordinary shares expected after the offering: up to 141,121,476 (based on 105,362,551 outstanding as of March 31, 2026 plus subsequent issuances through June 30, 2026). Trading price reference: last reported Nasdaq sale $1.81 on July 2, 2026.
ProQR Therapeutics N.V. received an updated ownership filing from Dutch investor Adrianus van Herk and affiliated entities. They report beneficial ownership of 15,384,250 ordinary shares, or about 10.9% of ProQR’s ordinary shares outstanding as of June 26, 2026.
The percentage change is due solely to an increase in ProQR’s total shares outstanding following issuances described in a recent Prospectus Supplement, not from new share purchases or sales by the Van Herk group. The group retains sole or shared voting and dispositive power over the same share amount, and reports no transactions in the past 60 days.
ProQR Therapeutics N.V. director Hinsch Gylvin Lykke received a grant of share options covering 14,595 Ordinary Shares. The options have an exercise price of $1.42 per share, based on the closing market price of the company’s ordinary shares on June 1, 2026.
The options were granted on June 2, 2026, with 25% of the underlying shares vesting and becoming exercisable on June 2, 2027. The remaining 75% vest in 12 substantially equal quarterly installments thereafter, contingent on Lykke’s continued service with ProQR.
ProQR Therapeutics N.V. director Bart Filius reported an open-market purchase of Ordinary Shares. On the reported date, he bought 150,000 Ordinary Shares at a price of $1.54 per share. Following this transaction, his directly held position in ProQR totals 150,000 Ordinary Shares.
ProQR Therapeutics entered an underwriting agreement for an underwritten registered direct offering of 27,624,310 ordinary shares at $1.81 per share. The company expects aggregate net proceeds of about $46.5 million from this offering, after underwriting discounts and expenses.
Concurrently, ProQR agreed to sell 5,100,780 additional shares to Eli Lilly in a private placement at the same price, for approximately $9.2 million. Lilly is subject to a lockup, standstill and receives registration rights, while ProQR plans to use the combined proceeds mainly for research, clinical development and general corporate purposes.
ProQR Therapeutics N.V. is offering 27,624,310 ordinary shares at a public offering price of $1.81 per share. Concurrently, ProQR has a separately negotiated private placement with Eli Lilly and Company for 5,100,780 ordinary shares at the same public offering price; that private placement is not registered as part of this offering but will close simultaneously, and the closing of the offering is not contingent on the private placement. The underwriters expect to deliver the shares on or about June 26, 2026. ProQR reports estimated net proceeds from the offering together with the concurrent private placement of approximately $55.8 million, and states it intends to use proceeds to fund research and clinical development, working capital, capital expenditures and other general corporate purposes. ProQR expects 141,119,032 ordinary shares to be outstanding immediately after this offering and the concurrent private placement.
ProQR Therapeutics reported positive Phase 1 target engagement data for AX-0810, its first Axiomer RNA editing candidate, in healthy volunteers. The multiple ascending dose study enrolled 33 participants, with AX-0810 showing dose-dependent NTCP modulation, including up to 8-fold increases in total bile acids versus a predefined 2-fold target threshold.
Concordant changes in conjugated bile acids, increased TUDCA after oral challenge, and unchanged hormone levels support on-target activity while preserving other NTCP functions. Safety and tolerability were favorable with no serious adverse events and pharmacokinetics showed an approximately eight-week half-life, suggesting sustained target engagement.
These data provide the first clinical validation of ProQR’s Axiomer RNA editing platform and support its NTCP franchise, including next-generation candidate AX-0811. ProQR outlines plans for AX-0811 Phase 1, an investigator-initiated biliary atresia trial, and a potentially registration-enabling Phase 2 program, alongside additional Axiomer-based pipeline candidates.